A Study to Evaluate Patients with TransthyretinMediated Amyloid Cardiomyopathy (ATTR CM)

Brief description of study

This study is for those diagnosed with transthyretin-mediated amyloid cardiomyopathy which is a disease caused by change in a protein called transthyretin (TTR). This change can either be sporadic which is known as wild-type (wtATTR-CM) or due to a mutation of the TTR gene which is hereditary (hATTR-CM). In both cases, these changes can cause the TTR to clump and build up in certain parts of your body such as your nervous system, stomach, intestines, and heart. This build up is called an amyloid deposit. Amyloid deposits can sometimes cause heart disease or neuropathy. When amyloid is deposited into the heart, it can result in a condition referred to as cardiomyopathy.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Cardiomyopathy
Age: Between 18 Years - 90 Years
Gender: All

Male and Female Age 18-90 Diagnosed with transthyretin-mediated amyloid cardiomyopathy

Updated on 09 Mar 2024. Study ID: 834757

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).